You are here:

ofatumumab (Arzerra)

Advice

in the absence of a submission from the holder of the marketing authorisation:

ofatumumab (Arzerra®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclosphosphamide.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: ofatumumab (Arzerra)
SMC Drug ID: 1237/17
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclosphosphamide.
BNF Category:
Sub Category: 8.2 Drugs affecting the immune response
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 10 April 2017

Back